Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

Phase 2 Completed 11 enrolled Aclaris Therapeutics, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.

Timeline

Start: 2017-12-14
Primary completion: 2019-06-20
Completion: 2019-06-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IFIDANCITINIB	Small molecule	—	Topical

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

Summary

Timeline

Drugs

Indications